{"id": "article-27346_0", "title": "Pneumococcal Vaccine -- Continuing Education Activity", "content": "The advent of pneumococcal vaccines has proven to be a significant advancement in treating and preventing a widespread and sometimes deadly disease process. The pneumococcal conjugate vaccines are recommended differently depending on the patient population. While both vaccine types are proven to stimulate long-lasting antibodies in immunocompromised adults, conjugate vaccines have been shown to provide some additional benefits, as will be covered here. This activity describes the mode of action of pneumococcal vaccines, including methods of administration, formulations, adverse event profiles, eligible patient populations, and monitoring, and highlights the role of the interprofessional team in the management of these patients.", "contents": "Pneumococcal Vaccine -- Continuing Education Activity. The advent of pneumococcal vaccines has proven to be a significant advancement in treating and preventing a widespread and sometimes deadly disease process. The pneumococcal conjugate vaccines are recommended differently depending on the patient population. While both vaccine types are proven to stimulate long-lasting antibodies in immunocompromised adults, conjugate vaccines have been shown to provide some additional benefits, as will be covered here. This activity describes the mode of action of pneumococcal vaccines, including methods of administration, formulations, adverse event profiles, eligible patient populations, and monitoring, and highlights the role of the interprofessional team in the management of these patients."}
{"id": "article-27346_1", "title": "Pneumococcal Vaccine -- Continuing Education Activity", "content": "Objectives: Identify the types of pneumococcal viruses requiring vaccinations. Summarize the absolute and relative contraindications of the pneumococcal vaccine. Review the methods of administering pneumococcal vaccination and eligible patients for each type of vaccine. Explain interprofessional team strategies for improving care coordination and communication to advance pneumococcal vaccination and improve patient outcomes. Access free multiple choice questions on this topic.", "contents": "Pneumococcal Vaccine -- Continuing Education Activity. Objectives: Identify the types of pneumococcal viruses requiring vaccinations. Summarize the absolute and relative contraindications of the pneumococcal vaccine. Review the methods of administering pneumococcal vaccination and eligible patients for each type of vaccine. Explain interprofessional team strategies for improving care coordination and communication to advance pneumococcal vaccination and improve patient outcomes. Access free multiple choice questions on this topic."}
{"id": "article-27346_2", "title": "Pneumococcal Vaccine -- Indications", "content": "Pneumococcal vaccines are vaccines that work against the bacteria Streptococcus pneumoniae . These vaccines come in two formulations, polysaccharide vaccine, and conjugate vaccine. [1] [2] The advent of pneumococcal vaccines\u00a0has proven to be a significant advancement in treating and preventing a widespread and sometimes deadly disease process. [3] [4] Currently, PCV13, PCV15, PPSV23, and PCV20 are used for immunization. The\u00a0CDC and ACIP have revised the recommendations for routine administration of the pneumococcal conjugate vaccine, which is reflected in the administration section. In 2021, PCV20 and PCV15 were approved by the FDA for adults aged 18 years and older based on clinical trials that compared antibody responses to PCV20 and PCV15 with those to PCV13. In 2022, FDA approved expanded indications for PCV15 to include individuals aged six weeks\u201317 years.\u00a0PCV15 is anticipated to decrease pneumococcal disease incidence in children\u00a0as it induces immunity against additional pneumococcal disease-causing serotypes. The ACIP (Advisory Committee on Immunization Practices) suggests either PCV20 alone or PCV15 in series with PPSV23 for adults 65 and older and 19\u00a0to 64 years with risk factors or underlying medical conditions. [5]", "contents": "Pneumococcal Vaccine -- Indications. Pneumococcal vaccines are vaccines that work against the bacteria Streptococcus pneumoniae . These vaccines come in two formulations, polysaccharide vaccine, and conjugate vaccine. [1] [2] The advent of pneumococcal vaccines\u00a0has proven to be a significant advancement in treating and preventing a widespread and sometimes deadly disease process. [3] [4] Currently, PCV13, PCV15, PPSV23, and PCV20 are used for immunization. The\u00a0CDC and ACIP have revised the recommendations for routine administration of the pneumococcal conjugate vaccine, which is reflected in the administration section. In 2021, PCV20 and PCV15 were approved by the FDA for adults aged 18 years and older based on clinical trials that compared antibody responses to PCV20 and PCV15 with those to PCV13. In 2022, FDA approved expanded indications for PCV15 to include individuals aged six weeks\u201317 years.\u00a0PCV15 is anticipated to decrease pneumococcal disease incidence in children\u00a0as it induces immunity against additional pneumococcal disease-causing serotypes. The ACIP (Advisory Committee on Immunization Practices) suggests either PCV20 alone or PCV15 in series with PPSV23 for adults 65 and older and 19\u00a0to 64 years with risk factors or underlying medical conditions. [5]"}
{"id": "article-27346_3", "title": "Pneumococcal Vaccine -- Indications", "content": "PCV13 (13-valent pneumococcal conjugate vaccine): PCV 13 provides active immunization against serotypes of Streptococcus pneumoniae (1, 3, 4, 5, 6A and 6B, 7F, 9V, 14, 19A, and 19F, 18C, and 23F). Indications vary according to age. Children six weeks -five years of age: Prevention of IPD (invasive pneumococcal disease) caused by Streptococcus pneumoniae and for the prevention of otitis media Children six years through seventeen years of age: Prevention of IPD caused by Streptococcus pneumoniae Adults \u226518 years: Prevention of IPD and pneumonia caused by Streptococcus pneumoniae . [6]", "contents": "Pneumococcal Vaccine -- Indications. PCV13 (13-valent pneumococcal conjugate vaccine): PCV 13 provides active immunization against serotypes of Streptococcus pneumoniae (1, 3, 4, 5, 6A and 6B, 7F, 9V, 14, 19A, and 19F, 18C, and 23F). Indications vary according to age. Children six weeks -five years of age: Prevention of IPD (invasive pneumococcal disease) caused by Streptococcus pneumoniae and for the prevention of otitis media Children six years through seventeen years of age: Prevention of IPD caused by Streptococcus pneumoniae Adults \u226518 years: Prevention of IPD and pneumonia caused by Streptococcus pneumoniae . [6]"}
{"id": "article-27346_4", "title": "Pneumococcal Vaccine -- Indications", "content": "PCV15 (15-valent pneumococcal conjugate vaccine): PCV 15 provides active immunization against serotypes of Streptococcus pneumoniae (1, 3, 4, 5, 6A and 6B, 7F, 9V, 14, 18C, 19A and 19F, 22F, 23F, and 33F). It is indicated for: The prevention of IPD caused by Streptococcus pneumoniae in individuals six weeks of age and older PCV13 and PCV15 can be used interchangeably. [7]", "contents": "Pneumococcal Vaccine -- Indications. PCV15 (15-valent pneumococcal conjugate vaccine): PCV 15 provides active immunization against serotypes of Streptococcus pneumoniae (1, 3, 4, 5, 6A and 6B, 7F, 9V, 14, 18C, 19A and 19F, 22F, 23F, and 33F). It is indicated for: The prevention of IPD caused by Streptococcus pneumoniae in individuals six weeks of age and older PCV13 and PCV15 can be used interchangeably. [7]"}
{"id": "article-27346_5", "title": "Pneumococcal Vaccine -- Indications", "content": "PCV20 (20-valent pneumococcal conjugate vaccine): PCV20 is recommended for active immunization against serotypes of Streptococcus pneumoniae (1, 3, 4, 5, 6A, and 6B, 7F, 8, 9V, 11A, 10A, 12F, 14, 15B, 18C, 19A and 19F, 22F, 23F, and 33F). PCV 20 is indicated for preventing pneumonia and invasive pneumococcal diseases in adults 18 years of age and older. [8]", "contents": "Pneumococcal Vaccine -- Indications. PCV20 (20-valent pneumococcal conjugate vaccine): PCV20 is recommended for active immunization against serotypes of Streptococcus pneumoniae (1, 3, 4, 5, 6A, and 6B, 7F, 8, 9V, 11A, 10A, 12F, 14, 15B, 18C, 19A and 19F, 22F, 23F, and 33F). PCV 20 is indicated for preventing pneumonia and invasive pneumococcal diseases in adults 18 years of age and older. [8]"}
{"id": "article-27346_6", "title": "Pneumococcal Vaccine -- Indications", "content": "PPSV23 (23-valent pneumococcal polysaccharide vaccine): PPSV 23 is recommended for active immunization for preventing pneumococcal disease caused by the 23 serotypes of streptococcus pneumoniae (1, 2, 4,\u00a03, 5, 6B, 7F, 8, 9N and 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A and 19F, 20, 22F, 23F, and 33F). PPSV23 is approved in individuals\u2265 50 age. PPSV 23 is also indicated in children\u2265 two years of age at high risk of pneumococcal infection. [9] [10] [11]", "contents": "Pneumococcal Vaccine -- Indications. PPSV23 (23-valent pneumococcal polysaccharide vaccine): PPSV 23 is recommended for active immunization for preventing pneumococcal disease caused by the 23 serotypes of streptococcus pneumoniae (1, 2, 4,\u00a03, 5, 6B, 7F, 8, 9N and 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A and 19F, 20, 22F, 23F, and 33F). PPSV23 is approved in individuals\u2265 50 age. PPSV 23 is also indicated in children\u2265 two years of age at high risk of pneumococcal infection. [9] [10] [11]"}
{"id": "article-27346_7", "title": "Pneumococcal Vaccine -- Mechanism of Action", "content": "Both vaccines promote active immunization against the serotypes of the conjugate and capsular polysaccharides contained in the formulation of the vaccine. Immunity develops approximately 2 to 3 weeks after vaccination and lasts five years. However, in children and the elderly, re-immunization may be necessary sooner.", "contents": "Pneumococcal Vaccine -- Mechanism of Action. Both vaccines promote active immunization against the serotypes of the conjugate and capsular polysaccharides contained in the formulation of the vaccine. Immunity develops approximately 2 to 3 weeks after vaccination and lasts five years. However, in children and the elderly, re-immunization may be necessary sooner."}
{"id": "article-27346_8", "title": "Pneumococcal Vaccine -- Mechanism of Action -- PCV13", "content": "This vaccine formulation\u00a0demonstrates improved antibody response compared to the pneumococcal polysaccharide vaccine because it contains purified capsular polysaccharides of pneumococcal serotypes conjugated to a carrier protein. PCV 13 actively immunizes against invasive disease caused by S. pneumoniae capsular serotypes\u00a01, 3, 4, 5, 6B, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F. All of the serotypes are individually conjugated to a CRM197 protein. [12]", "contents": "Pneumococcal Vaccine -- Mechanism of Action -- PCV13. This vaccine formulation\u00a0demonstrates improved antibody response compared to the pneumococcal polysaccharide vaccine because it contains purified capsular polysaccharides of pneumococcal serotypes conjugated to a carrier protein. PCV 13 actively immunizes against invasive disease caused by S. pneumoniae capsular serotypes\u00a01, 3, 4, 5, 6B, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F. All of the serotypes are individually conjugated to a CRM197 protein. [12]"}
{"id": "article-27346_9", "title": "Pneumococcal Vaccine -- Mechanism of Action -- PCV15", "content": "PCV15 contains polysaccharide serotypes 22F and 33F in addition to the PCV13 serotypes, conjugated to genetically detoxified diphtheria toxin. The randomized controlled trial in adults \u226550 years demonstrated that PCV15 met the noninferiority criteria compared with PCV13 for the 13 shared serotypes. PCV15 also had statistically significant responses for serotype three and PCV15-unique serotypes 22F and 33F.\u00a0Another randomized controlled trial included healthy\u00a0infants aged 42\u00a0to 90 days to assess the interchangeable use of PCV13 and PCV15. IgG geometric mean concentration for the 13 shared serotypes estimated was similar to those in children immunized with PCV13. In PCV-naive or partially vaccinated in the age group 7 months\u201317 years who received catch-up PCV doses, PCV15 elicited IgG concentrations similar to PCV13 for the 13 shared serotypes. PCV15 elicited higher IgG geometric mean concentration for 6 of 13 shared serotypes and the two unique serotypes in children with sickle cell disease. Additionally, among children with HIV infection, PCV15 produced higher IgG concentrations for two unique serotypes and 8 of 13 shared serotypes compared with PCV13. [13]", "contents": "Pneumococcal Vaccine -- Mechanism of Action -- PCV15. PCV15 contains polysaccharide serotypes 22F and 33F in addition to the PCV13 serotypes, conjugated to genetically detoxified diphtheria toxin. The randomized controlled trial in adults \u226550 years demonstrated that PCV15 met the noninferiority criteria compared with PCV13 for the 13 shared serotypes. PCV15 also had statistically significant responses for serotype three and PCV15-unique serotypes 22F and 33F.\u00a0Another randomized controlled trial included healthy\u00a0infants aged 42\u00a0to 90 days to assess the interchangeable use of PCV13 and PCV15. IgG geometric mean concentration for the 13 shared serotypes estimated was similar to those in children immunized with PCV13. In PCV-naive or partially vaccinated in the age group 7 months\u201317 years who received catch-up PCV doses, PCV15 elicited IgG concentrations similar to PCV13 for the 13 shared serotypes. PCV15 elicited higher IgG geometric mean concentration for 6 of 13 shared serotypes and the two unique serotypes in children with sickle cell disease. Additionally, among children with HIV infection, PCV15 produced higher IgG concentrations for two unique serotypes and 8 of 13 shared serotypes compared with PCV13. [13]"}
{"id": "article-27346_10", "title": "Pneumococcal Vaccine -- Mechanism of Action -- PCV20", "content": "PCV20 contains serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F, in addition to PCV13, conjugated to\u00a0detoxified diphtheria toxin.\u00a0PCV20 produced a strong immune response to all 20 vaccine serotypes in adults 18\u201349 years. PCV20\u00a0provides enhanced protection which is evident based on an opsonophagocytic activity assay. [14]", "contents": "Pneumococcal Vaccine -- Mechanism of Action -- PCV20. PCV20 contains serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F, in addition to PCV13, conjugated to\u00a0detoxified diphtheria toxin.\u00a0PCV20 produced a strong immune response to all 20 vaccine serotypes in adults 18\u201349 years. PCV20\u00a0provides enhanced protection which is evident based on an opsonophagocytic activity assay. [14]"}
{"id": "article-27346_11", "title": "Pneumococcal Vaccine -- Mechanism of Action -- PPSV 23", "content": "This vaccine formulation is the first pneumococcal vaccine formulated from a capsular polysaccharide. PPSV 23 contains 23 capsular polysaccharide types of S. pneumoniae, representing\u00a0at least 85% to 90% of pneumococcal disease isolates in the United States. It has shown a 50% to 80% efficacy in preventing invasive pneumococcal disease in adults. S. Pneumoniae serotypes are 1, 2, 3, 4, 5, 6B, 7F, 8, 9V, 9N, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. [15]", "contents": "Pneumococcal Vaccine -- Mechanism of Action -- PPSV 23. This vaccine formulation is the first pneumococcal vaccine formulated from a capsular polysaccharide. PPSV 23 contains 23 capsular polysaccharide types of S. pneumoniae, representing\u00a0at least 85% to 90% of pneumococcal disease isolates in the United States. It has shown a 50% to 80% efficacy in preventing invasive pneumococcal disease in adults. S. Pneumoniae serotypes are 1, 2, 3, 4, 5, 6B, 7F, 8, 9V, 9N, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. [15]"}
{"id": "article-27346_12", "title": "Pneumococcal Vaccine -- Administration", "content": "PCV 13, PCV 15, and PCV 20 are administered by IM route. PPSV 23 can be administered by IM or SC route. PCV13 and PCV15 are available in a single-dose prefilled syringe (0.5 mL). PCV13/PCV15 may be administered simultaneously with additional vaccines, including COVID-19. However, they must be prepared and administered in separate syringes and utilizing different injection locations. Vaccines\u00a0should be discarded\u00a0if there is\u00a0the presence of\u00a0particulate matter and discoloration in the solution. [16] [17] Hands should be cleansed with an alcohol-based antiseptic hand rub or with soap and water before preparing vaccines for administration. [18] [19] [20]", "contents": "Pneumococcal Vaccine -- Administration. PCV 13, PCV 15, and PCV 20 are administered by IM route. PPSV 23 can be administered by IM or SC route. PCV13 and PCV15 are available in a single-dose prefilled syringe (0.5 mL). PCV13/PCV15 may be administered simultaneously with additional vaccines, including COVID-19. However, they must be prepared and administered in separate syringes and utilizing different injection locations. Vaccines\u00a0should be discarded\u00a0if there is\u00a0the presence of\u00a0particulate matter and discoloration in the solution. [16] [17] Hands should be cleansed with an alcohol-based antiseptic hand rub or with soap and water before preparing vaccines for administration. [18] [19] [20]"}
{"id": "article-27346_13", "title": "Pneumococcal Vaccine -- Administration", "content": "Site: The deltoid muscle is the preferred location for PCV13/PCV15 vaccination in older children and PCV15/PCV20 vaccination in adults. The preferred injection site for PCV13/PCV15 for infants and young children is vastus lateralis in the anterolateral thigh. Vaccination schedule according to CDC and ACIP", "contents": "Pneumococcal Vaccine -- Administration. Site: The deltoid muscle is the preferred location for PCV13/PCV15 vaccination in older children and PCV15/PCV20 vaccination in adults. The preferred injection site for PCV13/PCV15 for infants and young children is vastus lateralis in the anterolateral thigh. Vaccination schedule according to CDC and ACIP"}
{"id": "article-27346_14", "title": "Pneumococcal Vaccine -- Administration -- Infants and children", "content": "CDC and ACIP suggest using PCV (PCV13 or PCV15) for children (2\u201359 months). PCV13 and PCV15 can be used interchangeably. PCV15 is not indicated for those who have received four doses of PCV13 or age-appropriate complete PCV13 vaccination series. It is important to note that the minimum age for this first dose is six weeks for PCV13/15 and 2 years for PPSV 23. Preterm infants should be vaccinated according to chronological age regardless of birth weight.", "contents": "Pneumococcal Vaccine -- Administration -- Infants and children. CDC and ACIP suggest using PCV (PCV13 or PCV15) for children (2\u201359 months). PCV13 and PCV15 can be used interchangeably. PCV15 is not indicated for those who have received four doses of PCV13 or age-appropriate complete PCV13 vaccination series. It is important to note that the minimum age for this first dose is six weeks for PCV13/15 and 2 years for PPSV 23. Preterm infants should be vaccinated according to chronological age regardless of birth weight."}
{"id": "article-27346_15", "title": "Pneumococcal Vaccine -- Administration -- Infants and children", "content": "Infants aged 2\u20136 months: Four doses of pneumococcal conjugate vaccine (PCV13 or PCV15) are recommended. Administer PCV13 or PCV15 to infants in a sequence of 4 doses (3 primary and one booster). The primary series consists of 3 doses of PCV. Infants obtaining the first dose at age \u22646 months should be administered three doses of PCV at intervals of approximately eight weeks. The minimum interval is of 4 weeks. The booster(fourth) dose is advised at age 12\u201315 months. It should be administered \u22658 weeks after the third dose. Hence the recommended schedule is one dose of PCV 13/PCV15 at 2, 4, 6 months, and 12\u00a0to 15 months.", "contents": "Pneumococcal Vaccine -- Administration -- Infants and children. Infants aged 2\u20136 months: Four doses of pneumococcal conjugate vaccine (PCV13 or PCV15) are recommended. Administer PCV13 or PCV15 to infants in a sequence of 4 doses (3 primary and one booster). The primary series consists of 3 doses of PCV. Infants obtaining the first dose at age \u22646 months should be administered three doses of PCV at intervals of approximately eight weeks. The minimum interval is of 4 weeks. The booster(fourth) dose is advised at age 12\u201315 months. It should be administered \u22658 weeks after the third dose. Hence the recommended schedule is one dose of PCV 13/PCV15 at 2, 4, 6 months, and 12\u00a0to 15 months."}
{"id": "article-27346_16", "title": "Pneumococcal Vaccine -- Administration -- Infants and children", "content": "Infants aged 7\u201311 months: If PCV is initiated at age 7\u00a0to 11 months, three doses (either PCV13 or PCV15) are advised. The first two doses should be administered with an interval of \u22654 weeks between doses. The third dose should be given at 12\u201315 months; an interval of \u22658 weeks between the second and third doses is advised.", "contents": "Pneumococcal Vaccine -- Administration -- Infants and children. Infants aged 7\u201311 months: If PCV is initiated at age 7\u00a0to 11 months, three doses (either PCV13 or PCV15) are advised. The first two doses should be administered with an interval of \u22654 weeks between doses. The third dose should be given at 12\u201315 months; an interval of \u22658 weeks between the second and third doses is advised."}
{"id": "article-27346_17", "title": "Pneumococcal Vaccine -- Administration -- Infants and children", "content": "Children aged 12\u201323 months: If PCV is initiated at 12\u00a0to 23 months of age, two doses (either PCV13 or PCV15) are suggested, and an interval of \u22658 weeks between doses is advised.", "contents": "Pneumococcal Vaccine -- Administration -- Infants and children. Children aged 12\u201323 months: If PCV is initiated at 12\u00a0to 23 months of age, two doses (either PCV13 or PCV15) are suggested, and an interval of \u22658 weeks between doses is advised."}
{"id": "article-27346_18", "title": "Pneumococcal Vaccine -- Administration -- Infants and children", "content": "Children aged 24\u201371 months: Unvaccinated and healthy children aged 24\u00a0to 59 months be administered a single dose of PCV (PCV13 /PCV15). Unvaccinated children (24\u00a0to 71 months) with any risk condition should receive two doses of PCV (PCV13 or PCV15), and an interval of \u22658 weeks between two doses is recommended.", "contents": "Pneumococcal Vaccine -- Administration -- Infants and children. Children aged 24\u201371 months: Unvaccinated and healthy children aged 24\u00a0to 59 months be administered a single dose of PCV (PCV13 /PCV15). Unvaccinated children (24\u00a0to 71 months) with any risk condition should receive two doses of PCV (PCV13 or PCV15), and an interval of \u22658 weeks between two doses is recommended."}
{"id": "article-27346_19", "title": "Pneumococcal Vaccine -- Administration -- Infants and children", "content": "Children and adolescents aged 6\u201318 years with CSF leak, immunocompromising condition, or cochlear implant: If a dose of PCV13/PCV15 has not been given earlier, a single dose of PCV13 or PCV15 is advised, regardless of previously received PPSV23 or PCV7.", "contents": "Pneumococcal Vaccine -- Administration -- Infants and children. Children and adolescents aged 6\u201318 years with CSF leak, immunocompromising condition, or cochlear implant: If a dose of PCV13/PCV15 has not been given earlier, a single dose of PCV13 or PCV15 is advised, regardless of previously received PPSV23 or PCV7."}
{"id": "article-27346_20", "title": "Pneumococcal Vaccine -- Administration -- Infants and children", "content": "Hematopoietic stem cell transplants: Recipients of stem cell transplants are advised to receive 3 PCV doses followed by a dose of PPSV23 starting 3\u00a0to 6 months after the transplant. In children with graft-versus-host disease(GVHD), PPSV23 can be substituted with a fourth dose of PCV. [5]", "contents": "Pneumococcal Vaccine -- Administration -- Infants and children. Hematopoietic stem cell transplants: Recipients of stem cell transplants are advised to receive 3 PCV doses followed by a dose of PPSV23 starting 3\u00a0to 6 months after the transplant. In children with graft-versus-host disease(GVHD), PPSV23 can be substituted with a fourth dose of PCV. [5]"}
{"id": "article-27346_21", "title": "Pneumococcal Vaccine -- Administration -- Children 2 to 5 Years", "content": "CDC suggests pneumococcal vaccination for medical conditions that can increase the risk of pneumococcal infection. These conditions are listed below: CSF leak Cochlear implant Chronic heart disease, cardiac failure, and particularly cyanotic congenital heart disease Chronic lung disease; asthma treated with chronic high-dose oral corticosteroids Diabetes mellitus", "contents": "Pneumococcal Vaccine -- Administration -- Children 2 to 5 Years. CDC suggests pneumococcal vaccination for medical conditions that can increase the risk of pneumococcal infection. These conditions are listed below: CSF leak Cochlear implant Chronic heart disease, cardiac failure, and particularly cyanotic congenital heart disease Chronic lung disease; asthma treated with chronic high-dose oral corticosteroids Diabetes mellitus"}
{"id": "article-27346_22", "title": "Pneumococcal Vaccine -- Administration -- For above mentioned medical conditions CDC suggests:", "content": "Administering two doses of either PCV13 or PCV15 if children are unvaccinated or received an incomplete pneumococcal conjugate vaccine series with <3 doses before 24 months of age. Administer the second dose at least eight weeks after the first dose. Give one dose of PCV13 or PCV15 if patients have been administered three doses of a PCV before 12 months but have yet to receive a fourth booster dose. Give one dose of PPSV23 at least eight weeks after completing the PCV series.", "contents": "Pneumococcal Vaccine -- Administration -- For above mentioned medical conditions CDC suggests:. Administering two doses of either PCV13 or PCV15 if children are unvaccinated or received an incomplete pneumococcal conjugate vaccine series with <3 doses before 24 months of age. Administer the second dose at least eight weeks after the first dose. Give one dose of PCV13 or PCV15 if patients have been administered three doses of a PCV before 12 months but have yet to receive a fourth booster dose. Give one dose of PPSV23 at least eight weeks after completing the PCV series."}
{"id": "article-27346_23", "title": "Pneumococcal Vaccine -- Administration -- High-risk medical conditions are listed below:", "content": "Chronic renal failure or nephrotic syndrome Sickle cell disease or other hemoglobinopathies Congenital immunodeficiency Congenital or acquired asplenia, or splenic dysfunction Diseases associated with the treatment of immunosuppressive drugs or radiation therapy Leukemia Solid organ transplant Hodgkin disease Lymphoma Malignancy HIV infection", "contents": "Pneumococcal Vaccine -- Administration -- High-risk medical conditions are listed below:. Chronic renal failure or nephrotic syndrome Sickle cell disease or other hemoglobinopathies Congenital immunodeficiency Congenital or acquired asplenia, or splenic dysfunction Diseases associated with the treatment of immunosuppressive drugs or radiation therapy Leukemia Solid organ transplant Hodgkin disease Lymphoma Malignancy HIV infection"}
{"id": "article-27346_24", "title": "Pneumococcal Vaccine -- Administration -- For high-risk medical conditions, CDC suggests:", "content": "Administer two doses of (PCV13 or PCV15) if patients are unvaccinated or received an incomplete pneumococcal conjugate vaccine series with <3 doses before 24 months of age. Administer the second dose at least eight weeks after the first. Administer one dose of PCV13 or PCV15 if they received three doses of a pneumococcal conjugate vaccine before 12 months but have yet to receive their fourth booster dose. Administer two doses of PPSV23 after the PCV series is complete. Give the first dose at least eight weeks after any previous PCV dose, then give the second dose of PPSV23 at least five years after the first PPSV23 dose .", "contents": "Pneumococcal Vaccine -- Administration -- For high-risk medical conditions, CDC suggests:. Administer two doses of (PCV13 or PCV15) if patients are unvaccinated or received an incomplete pneumococcal conjugate vaccine series with <3 doses before 24 months of age. Administer the second dose at least eight weeks after the first. Administer one dose of PCV13 or PCV15 if they received three doses of a pneumococcal conjugate vaccine before 12 months but have yet to receive their fourth booster dose. Administer two doses of PPSV23 after the PCV series is complete. Give the first dose at least eight weeks after any previous PCV dose, then give the second dose of PPSV23 at least five years after the first PPSV23 dose ."}
{"id": "article-27346_25", "title": "Pneumococcal Vaccine -- Administration -- For a cerebrospinal fluid leak or cochlear implant, CDC suggests", "content": "Administer one dose of either PCV13 or PCV15 if the patients have not received any doses of a PCV vaccine. PCV13/PCV15 should be administered before PPSV23. Administer one dose of PPSV23 (if not already given before in childhood)\u2265 eight weeks after PCV13 or PCV15.", "contents": "Pneumococcal Vaccine -- Administration -- For a cerebrospinal fluid leak or cochlear implant, CDC suggests. Administer one dose of either PCV13 or PCV15 if the patients have not received any doses of a PCV vaccine. PCV13/PCV15 should be administered before PPSV23. Administer one dose of PPSV23 (if not already given before in childhood)\u2265 eight weeks after PCV13 or PCV15."}
{"id": "article-27346_26", "title": "Pneumococcal Vaccine -- Administration -- For\u00a0 high-risk medical conditions mentioned above, CDC suggests", "content": "Administer one dose of either PCV13 or PCV15 if the patients have not received any doses of a PCV vaccine. Administer PCV13 or PCV15 before giving any recommended doses of PPSV23. Administer two doses of PPSV23. The first dose of PPSV23 should be administered at least eight weeks after any initial PCV dose. The second dose of PPSV23 should be administered only five years after the first dose of PPSV23.", "contents": "Pneumococcal Vaccine -- Administration -- For\u00a0 high-risk medical conditions mentioned above, CDC suggests. Administer one dose of either PCV13 or PCV15 if the patients have not received any doses of a PCV vaccine. Administer PCV13 or PCV15 before giving any recommended doses of PPSV23. Administer two doses of PPSV23. The first dose of PPSV23 should be administered at least eight weeks after any initial PCV dose. The second dose of PPSV23 should be administered only five years after the first dose of PPSV23."}
{"id": "article-27346_27", "title": "Pneumococcal Vaccine -- Administration -- For a child with", "content": "Chronic heart disease, cardiac failure, and particularly cyanotic congenital heart disease Chronic lung disease; asthma treated with chronic high-dose oral corticosteroids Diabetes mellitus", "contents": "Pneumococcal Vaccine -- Administration -- For a child with. Chronic heart disease, cardiac failure, and particularly cyanotic congenital heart disease Chronic lung disease; asthma treated with chronic high-dose oral corticosteroids Diabetes mellitus"}
{"id": "article-27346_28", "title": "Pneumococcal Vaccine -- Administration -- CDC suggests", "content": "Administering one dose of PPSV23 (if not already given earlier in childhood).", "contents": "Pneumococcal Vaccine -- Administration -- CDC suggests. Administering one dose of PPSV23 (if not already given earlier in childhood)."}
{"id": "article-27346_29", "title": "Pneumococcal Vaccine -- Administration -- Adults 19 to 64 Years", "content": "CDC advises pneumococcal vaccination for adults 19-64 years old with certain chronic medical diseases or high-risk factors: Alcoholism CSF leak Chronic liver disease Chronic lung disease, including COPD and asthma Chronic heart disease, including CHF and cardiomyopathies Cigarette smoking Cochlear implant Diabetes mellitus Congenital or acquired asplenia* Congenital or acquired immunodeficiency* Chronic renal failure* Malignancy* Hodgkin disease* HIV infection* Iatrogenic immunosuppression from radiation therapy and chronic systemic corticosteroids* Lymphoma* Leukemia* Multiple myeloma* Nephrotic syndrome* Solid organ transplant* Sickle cell disease or hemoglobinopathies* *Indicates immunocompromising conditions", "contents": "Pneumococcal Vaccine -- Administration -- Adults 19 to 64 Years. CDC advises pneumococcal vaccination for adults 19-64 years old with certain chronic medical diseases or high-risk factors: Alcoholism CSF leak Chronic liver disease Chronic lung disease, including COPD and asthma Chronic heart disease, including CHF and cardiomyopathies Cigarette smoking Cochlear implant Diabetes mellitus Congenital or acquired asplenia* Congenital or acquired immunodeficiency* Chronic renal failure* Malignancy* Hodgkin disease* HIV infection* Iatrogenic immunosuppression from radiation therapy and chronic systemic corticosteroids* Lymphoma* Leukemia* Multiple myeloma* Nephrotic syndrome* Solid organ transplant* Sickle cell disease or hemoglobinopathies* *Indicates immunocompromising conditions"}
{"id": "article-27346_30", "title": "Pneumococcal Vaccine -- Administration -- For adults who have not been given any pneumococcal vaccine or have received only PCV7, CDC recommends", "content": "Administer 1 dose of PCV15/PCV20. If PCV15 is administered to the patient, it should be followed by PPSV23 after one year. The minimum interval between 2 doses is eight weeks and is used in patients with an immunocompromising state, CSF leak, and cochlear implant. It is important to note that if PCV20 is administered, PPSV23 is not indicated for the patient.", "contents": "Pneumococcal Vaccine -- Administration -- For adults who have not been given any pneumococcal vaccine or have received only PCV7, CDC recommends. Administer 1 dose of PCV15/PCV20. If PCV15 is administered to the patient, it should be followed by PPSV23 after one year. The minimum interval between 2 doses is eight weeks and is used in patients with an immunocompromising state, CSF leak, and cochlear implant. It is important to note that if PCV20 is administered, PPSV23 is not indicated for the patient."}
{"id": "article-27346_31", "title": "Pneumococcal Vaccine -- Administration -- For adults who have received PPSV23 only, CDC suggests", "content": "Administer 1 dose of PCV15 or PCV20. The PCV15 or PCV20 dose should be given at least one year after the last PPSV23 vaccination.", "contents": "Pneumococcal Vaccine -- Administration -- For adults who have received PPSV23 only, CDC suggests. Administer 1 dose of PCV15 or PCV20. The PCV15 or PCV20 dose should be given at least one year after the last PPSV23 vaccination."}
{"id": "article-27346_32", "title": "Pneumococcal Vaccine -- Administration -- For adults who have only received PCV13, CDC suggests", "content": "Administer a single dose of PCV20 at least one year after PCV13. The second option is administering a single dose of PPSV23 at least eight weeks after the previous vaccination with PCV13. Patients with immunocompromising conditions require additional doses of PPSV23. The second dose of PPSV23 is administered at least five years after the first. The third dose of PPSV23 is given at \u2265 65 years (minimum interval of five years from the second dose of PPSV23). A third dose is not indicated if a patient is \u2265 65 years old when the second dose is administered. Patients with risk factors or medical conditions listed above will require a second dose of PPSV23 at age \u2265 65 years.", "contents": "Pneumococcal Vaccine -- Administration -- For adults who have only received PCV13, CDC suggests. Administer a single dose of PCV20 at least one year after PCV13. The second option is administering a single dose of PPSV23 at least eight weeks after the previous vaccination with PCV13. Patients with immunocompromising conditions require additional doses of PPSV23. The second dose of PPSV23 is administered at least five years after the first. The third dose of PPSV23 is given at \u2265 65 years (minimum interval of five years from the second dose of PPSV23). A third dose is not indicated if a patient is \u2265 65 years old when the second dose is administered. Patients with risk factors or medical conditions listed above will require a second dose of PPSV23 at age \u2265 65 years."}
{"id": "article-27346_33", "title": "Pneumococcal Vaccine -- Administration -- For adults who have received PCV13 and one dose of PPSV23, CDC suggests", "content": "Administer one dose of PCV20 at least five years after the last pneumococcal vaccine. The minimum interval (1 year since the last PCV13 dose and five years since the last PPSV23 dose) can be considered in patients with a cochlear implant, CSF leak, or immunocompromising condition. The second option is administering PPSV23 at least eight weeks after PCV13 and five years after PPSV23 if patients have immunocompromising conditions. Patients with an immunocompromising condition will require an additional third dose of PPSV23 at age \u226565 years. (minimum interval of five years since the second dose of PPSV23).", "contents": "Pneumococcal Vaccine -- Administration -- For adults who have received PCV13 and one dose of PPSV23, CDC suggests. Administer one dose of PCV20 at least five years after the last pneumococcal vaccine. The minimum interval (1 year since the last PCV13 dose and five years since the last PPSV23 dose) can be considered in patients with a cochlear implant, CSF leak, or immunocompromising condition. The second option is administering PPSV23 at least eight weeks after PCV13 and five years after PPSV23 if patients have immunocompromising conditions. Patients with an immunocompromising condition will require an additional third dose of PPSV23 at age \u226565 years. (minimum interval of five years since the second dose of PPSV23)."}
{"id": "article-27346_34", "title": "Pneumococcal Vaccine -- Administration -- For adults\u2265 65 years who have not been administered any pneumococcal vaccine or have received only the PCV7 vaccine, CDC suggests:", "content": "Administer 1 dose of PCV15 or PCV20. If PCV15 is used, it is followed by PPSV23 at least one year later. The minimum period can be reduced to eight weeks in adults with an immunocompromising condition, CSF leak, or cochlear implant. If PCV20 is used, then PPSV23 is not indicated.", "contents": "Pneumococcal Vaccine -- Administration -- For adults\u2265 65 years who have not been administered any pneumococcal vaccine or have received only the PCV7 vaccine, CDC suggests:. Administer 1 dose of PCV15 or PCV20. If PCV15 is used, it is followed by PPSV23 at least one year later. The minimum period can be reduced to eight weeks in adults with an immunocompromising condition, CSF leak, or cochlear implant. If PCV20 is used, then PPSV23 is not indicated."}
{"id": "article-27346_35", "title": "Pneumococcal Vaccine -- Administration -- For adults \u226565 years who have only received PPSV23, CDC suggests:", "content": "Administer 1 dose of PCV15 or PCV20. The PCV15 or PCV20 should be administered at least one year after the PPSV23. An additional dose of PPSV23 is not required.", "contents": "Pneumococcal Vaccine -- Administration -- For adults \u226565 years who have only received PPSV23, CDC suggests:. Administer 1 dose of PCV15 or PCV20. The PCV15 or PCV20 should be administered at least one year after the PPSV23. An additional dose of PPSV23 is not required."}
{"id": "article-27346_36", "title": "Pneumococcal Vaccine -- Administration -- For adults \u226565 years who have been administered only PCV13, CDC suggests two options:", "content": "1 . Administer one dose of PCV20 at least one year after PCV13 2. Administer one dose of PPSV23 at least one year after PCV13. The minimum interval can be reduced to eight weeks for a CSF leak, cochlear implant, or an immunocompromising condition.", "contents": "Pneumococcal Vaccine -- Administration -- For adults \u226565 years who have been administered only PCV13, CDC suggests two options:. 1 . Administer one dose of PCV20 at least one year after PCV13 2. Administer one dose of PPSV23 at least one year after PCV13. The minimum interval can be reduced to eight weeks for a CSF leak, cochlear implant, or an immunocompromising condition."}
{"id": "article-27346_37", "title": "Pneumococcal Vaccine -- Administration -- For adults \u226565 years who have been administered PCV13 regardless of age and PPSV23 before age 65 years, the CDC suggests two options:", "content": "Administer one dose of PCV20 at least five years after the last pneumococcal vaccine. The minimum interval (one year since the last PCV13 dose and five years since the last PPSV23 dose) is considered in patients with a cochlear implant, CSF leak, or immunocompromising condition. Administer one dose of PPSV23 at least five years after the last pneumococcal vaccine. The minimum interval (8 weeks since the last PCV13 vaccination and five years since the last PPSV23 vaccination) is considered in patients with a cochlear implant, CSF leak, or immunocompromising condition.", "contents": "Pneumococcal Vaccine -- Administration -- For adults \u226565 years who have been administered PCV13 regardless of age and PPSV23 before age 65 years, the CDC suggests two options:. Administer one dose of PCV20 at least five years after the last pneumococcal vaccine. The minimum interval (one year since the last PCV13 dose and five years since the last PPSV23 dose) is considered in patients with a cochlear implant, CSF leak, or immunocompromising condition. Administer one dose of PPSV23 at least five years after the last pneumococcal vaccine. The minimum interval (8 weeks since the last PCV13 vaccination and five years since the last PPSV23 vaccination) is considered in patients with a cochlear implant, CSF leak, or immunocompromising condition."}
{"id": "article-27346_38", "title": "Pneumococcal Vaccine -- Administration", "content": "Shared decision-making: For adults \u2265 65 years who have been administered PCV13 at any age and PPSV23 at or after age 65 years, CDC suggests shared clinical decision-making. If the clinician and patient determine PCV20 is appropriate, PCV20 should be administered at least five years after the previous pneumococcal vaccine.", "contents": "Pneumococcal Vaccine -- Administration. Shared decision-making: For adults \u2265 65 years who have been administered PCV13 at any age and PPSV23 at or after age 65 years, CDC suggests shared clinical decision-making. If the clinician and patient determine PCV20 is appropriate, PCV20 should be administered at least five years after the previous pneumococcal vaccine."}
{"id": "article-27346_39", "title": "Pneumococcal Vaccine -- Administration -- Specific Patient Populations", "content": "Hepatic Impairment: The ACIP advises pneumococcal vaccination in patients with chronic liver disease. [21] Renal Impairment: CKD patients\u00a0naive in pneumococcal immunization should be administered\u00a0PCV13, followed by a dose of PPSV23 at eight weeks and 2nd dose of PPSV23 after five years. [22]", "contents": "Pneumococcal Vaccine -- Administration -- Specific Patient Populations. Hepatic Impairment: The ACIP advises pneumococcal vaccination in patients with chronic liver disease. [21] Renal Impairment: CKD patients\u00a0naive in pneumococcal immunization should be administered\u00a0PCV13, followed by a dose of PPSV23 at eight weeks and 2nd dose of PPSV23 after five years. [22]"}
{"id": "article-27346_40", "title": "Pneumococcal Vaccine -- Administration -- Specific Patient Populations", "content": "Pregnancy Considerations: Clinical\u00a0information on the safety of PCV-20 and PCV-15(conjugate vaccines) during pregnancy is inadequate. PPSV23\u00a0increases antibody titers in infants. ACOG(The American College of Obstetricians and Gynecologists) recommends PPSV23 in patients with\u00a0diabetes, heart disease, sickle cell anemia, and lung disease. [23]", "contents": "Pneumococcal Vaccine -- Administration -- Specific Patient Populations. Pregnancy Considerations: Clinical\u00a0information on the safety of PCV-20 and PCV-15(conjugate vaccines) during pregnancy is inadequate. PPSV23\u00a0increases antibody titers in infants. ACOG(The American College of Obstetricians and Gynecologists) recommends PPSV23 in patients with\u00a0diabetes, heart disease, sickle cell anemia, and lung disease. [23]"}
{"id": "article-27346_41", "title": "Pneumococcal Vaccine -- Administration -- Specific Patient Populations", "content": "Breastfeeding Considerations: The CDC suggests that vaccines administered to a nursing mother do not impact breastfeeding safety for mothers or infants. Breastfeeding is not a contraindication to the administration of the pneumococcal vaccines. Immunization during the third trimester of pregnancy increases the pneumococcal antibodies in breast milk. Breastfed infants should be vaccinated as suggested by ACIP and CDC. [24] Pediatric Patients: The safety and\u00a0efficacy of\u00a0PCV13 in children < 6 weeks of age have not been demonstrated.", "contents": "Pneumococcal Vaccine -- Administration -- Specific Patient Populations. Breastfeeding Considerations: The CDC suggests that vaccines administered to a nursing mother do not impact breastfeeding safety for mothers or infants. Breastfeeding is not a contraindication to the administration of the pneumococcal vaccines. Immunization during the third trimester of pregnancy increases the pneumococcal antibodies in breast milk. Breastfed infants should be vaccinated as suggested by ACIP and CDC. [24] Pediatric Patients: The safety and\u00a0efficacy of\u00a0PCV13 in children < 6 weeks of age have not been demonstrated."}
{"id": "article-27346_42", "title": "Pneumococcal Vaccine -- Administration -- Specific Patient Populations", "content": "Elderly\u00a0Patients: For PPSV 23, AEFI(adverse events following immunization) is\u00a0higher following revaccination\u00a0compared to initial vaccination. Consequently, routine revaccination of PPSV23 in immunocompetent patients>65 years of age\u00a0is not advised.", "contents": "Pneumococcal Vaccine -- Administration -- Specific Patient Populations. Elderly\u00a0Patients: For PPSV 23, AEFI(adverse events following immunization) is\u00a0higher following revaccination\u00a0compared to initial vaccination. Consequently, routine revaccination of PPSV23 in immunocompetent patients>65 years of age\u00a0is not advised."}
{"id": "article-27346_43", "title": "Pneumococcal Vaccine -- Adverse Effects", "content": "There are reports of the following adverse effects in different age groups. Following are the reports of common adverse events following immunization (AEFI). [25]", "contents": "Pneumococcal Vaccine -- Adverse Effects. There are reports of the following adverse effects in different age groups. Following are the reports of common adverse events following immunization (AEFI). [25]"}
{"id": "article-27346_44", "title": "Pneumococcal Vaccine -- Adverse Effects -- PCV13", "content": "Infants and toddlers Irritability Injection site tenderness Decreased appetite Sleep alterations Fever Injection site redness Injection site swelling", "contents": "Pneumococcal Vaccine -- Adverse Effects -- PCV13. Infants and toddlers Irritability Injection site tenderness Decreased appetite Sleep alterations Fever Injection site redness Injection site swelling"}
{"id": "article-27346_45", "title": "Pneumococcal Vaccine -- Adverse Effects -- Children 5 to 17 Years", "content": "Injection site tenderness, redness, and swelling Irritability Decreased appetite Sleep alterations Fever", "contents": "Pneumococcal Vaccine -- Adverse Effects -- Children 5 to 17 Years. Injection site tenderness, redness, and swelling Irritability Decreased appetite Sleep alterations Fever"}
{"id": "article-27346_46", "title": "Pneumococcal Vaccine -- Adverse Effects -- Adults 18 Years\u00a0and Older", "content": "Pain, redness, and swelling at the injection site Fatigue Headache Muscle pain Joint pain Decreased appetite Limitation of arm movement Vomiting Fever Chills Rash", "contents": "Pneumococcal Vaccine -- Adverse Effects -- Adults 18 Years\u00a0and Older. Pain, redness, and swelling at the injection site Fatigue Headache Muscle pain Joint pain Decreased appetite Limitation of arm movement Vomiting Fever Chills Rash"}
{"id": "article-27346_47", "title": "Pneumococcal Vaccine -- Adverse Effects -- Children 2 to 15 months", "content": "Injection-site erythema, induration, and\u00a0swelling Irritability Somnolence Fever Decreased appetite", "contents": "Pneumococcal Vaccine -- Adverse Effects -- Children 2 to 15 months. Injection-site erythema, induration, and\u00a0swelling Irritability Somnolence Fever Decreased appetite"}
{"id": "article-27346_48", "title": "Pneumococcal Vaccine -- Adverse Effects -- Children and adolescents 2 through 17 years of age", "content": "Injection-site pain, erythema,\u00a0swelling, and induration Myalgia Fatigue Headache", "contents": "Pneumococcal Vaccine -- Adverse Effects -- Children and adolescents 2 through 17 years of age. Injection-site pain, erythema,\u00a0swelling, and induration Myalgia Fatigue Headache"}
{"id": "article-27346_49", "title": "Pneumococcal Vaccine -- Adverse Effects -- Adults 18 years and older", "content": "Injection-site pain, swelling, erythema Fatigue Myalgia Headache Arthralgia", "contents": "Pneumococcal Vaccine -- Adverse Effects -- Adults 18 years and older. Injection-site pain, swelling, erythema Fatigue Myalgia Headache Arthralgia"}
{"id": "article-27346_50", "title": "Pneumococcal Vaccine -- Adverse Effects -- PCV20", "content": "Pain and swelling at the injection site fatigue headache muscle pain arthralgia", "contents": "Pneumococcal Vaccine -- Adverse Effects -- PCV20. Pain and swelling at the injection site fatigue headache muscle pain arthralgia"}
{"id": "article-27346_51", "title": "Pneumococcal Vaccine -- Adverse Effects -- PPSV23", "content": "Injection site pain/soreness/tenderness Injection site induration/swelling Headache Injection site erythema Fatigue/weakness Myalgia", "contents": "Pneumococcal Vaccine -- Adverse Effects -- PPSV23. Injection site pain/soreness/tenderness Injection site induration/swelling Headache Injection site erythema Fatigue/weakness Myalgia"}
{"id": "article-27346_52", "title": "Pneumococcal Vaccine -- Adverse Effects -- Interactions with drugs and vaccines", "content": "Concomitant administration of PPSV23 and live zoster vaccine showed a reduced immune response to the live zoster vaccine. The recommendation is\u00a0for administrations to be\u00a0at least four weeks apart. [26] Immunosuppressive treatment:\u00a0Patients\u00a0on immunosuppressive therapy, including corticosteroids, chemotherapy, and radiation therapy, may\u00a0have diminished seroprotection\u00a0to the pneumococcal vaccine. A booster dose may be considered according to guidelines. [27] Antipyretics: Antipyretics blunts\u00a0the\u00a0immune\u00a0response to some serotypes following immunization of PCV 13. However,\u00a0this interaction\u00a0requires\u00a0significant additional\u00a0research. [28]", "contents": "Pneumococcal Vaccine -- Adverse Effects -- Interactions with drugs and vaccines. Concomitant administration of PPSV23 and live zoster vaccine showed a reduced immune response to the live zoster vaccine. The recommendation is\u00a0for administrations to be\u00a0at least four weeks apart. [26] Immunosuppressive treatment:\u00a0Patients\u00a0on immunosuppressive therapy, including corticosteroids, chemotherapy, and radiation therapy, may\u00a0have diminished seroprotection\u00a0to the pneumococcal vaccine. A booster dose may be considered according to guidelines. [27] Antipyretics: Antipyretics blunts\u00a0the\u00a0immune\u00a0response to some serotypes following immunization of PCV 13. However,\u00a0this interaction\u00a0requires\u00a0significant additional\u00a0research. [28]"}
{"id": "article-27346_53", "title": "Pneumococcal Vaccine -- Contraindications", "content": "PCV13 and PPSV23 contraindications include severe allergic or anaphylactic reactions to any component of the formulation of the vaccine or any diphtheria toxoid-containing vaccine.\u00a0Pregnancy is not a contraindication to vaccination. Pregnant women at high risk of infection should receive the vaccination. [29] Similarly,\u00a0severe allergic reactions to\u00a0PCV 20 or diphtheria toxoid are contraindications to using PCV 20.", "contents": "Pneumococcal Vaccine -- Contraindications. PCV13 and PPSV23 contraindications include severe allergic or anaphylactic reactions to any component of the formulation of the vaccine or any diphtheria toxoid-containing vaccine.\u00a0Pregnancy is not a contraindication to vaccination. Pregnant women at high risk of infection should receive the vaccination. [29] Similarly,\u00a0severe allergic reactions to\u00a0PCV 20 or diphtheria toxoid are contraindications to using PCV 20."}
{"id": "article-27346_54", "title": "Pneumococcal Vaccine -- Contraindications -- Warnings and Precautions", "content": "PCV20: Patients with altered immunocompetence may have decreased immune responses to\u00a0PCV20. PPSV23: Use caution\u00a0in\u00a0severely compromised pulmonary and cardiovascular function, as any systemic reaction\u00a0can lead to\u00a0significant risk to the patient. PCV13 and PCV15: Apnea after vaccination has been\u00a0noted\u00a0in premature infants. These\u00a0infants should be\u00a0observed\u00a0for 48 hours after immunization. [30]", "contents": "Pneumococcal Vaccine -- Contraindications -- Warnings and Precautions. PCV20: Patients with altered immunocompetence may have decreased immune responses to\u00a0PCV20. PPSV23: Use caution\u00a0in\u00a0severely compromised pulmonary and cardiovascular function, as any systemic reaction\u00a0can lead to\u00a0significant risk to the patient. PCV13 and PCV15: Apnea after vaccination has been\u00a0noted\u00a0in premature infants. These\u00a0infants should be\u00a0observed\u00a0for 48 hours after immunization. [30]"}
{"id": "article-27346_55", "title": "Pneumococcal Vaccine -- Monitoring", "content": "For the first 15 minutes\u00a0following pneumococcal vaccine administration, patients require monitoring for allergic reactions\u00a0such as anaphylaxis and syncope.\u00a0Adverse events after the vaccine administration should be notified to the Vaccine Adverse Event Reporting System (VAERS). [31] For catch-up vaccination and subsequent visits, clinicians can use the PneumoRecs VaxAdvisor application developed by the CDC. [32] In addition, vaccine safety is monitored by\u00a0Vaccine Safety Datalink (VSD) from electronic health records at eight healthcare systems. [33]", "contents": "Pneumococcal Vaccine -- Monitoring. For the first 15 minutes\u00a0following pneumococcal vaccine administration, patients require monitoring for allergic reactions\u00a0such as anaphylaxis and syncope.\u00a0Adverse events after the vaccine administration should be notified to the Vaccine Adverse Event Reporting System (VAERS). [31] For catch-up vaccination and subsequent visits, clinicians can use the PneumoRecs VaxAdvisor application developed by the CDC. [32] In addition, vaccine safety is monitored by\u00a0Vaccine Safety Datalink (VSD) from electronic health records at eight healthcare systems. [33]"}
{"id": "article-27346_56", "title": "Pneumococcal Vaccine -- Toxicity", "content": "There is no overdose risk with the administration of the vaccine. Careful dosing, administration, and adherence to the vaccine guidelines should preclude any chance of overdosing. Preclinical studies\u00a0demonstrated no toxicity in rats when the modified pneumococcal vaccine\u00a0was administered subcutaneously\u00a0three times\u00a0in 2-weeks at a supratherapeutic dose. [34]", "contents": "Pneumococcal Vaccine -- Toxicity. There is no overdose risk with the administration of the vaccine. Careful dosing, administration, and adherence to the vaccine guidelines should preclude any chance of overdosing. Preclinical studies\u00a0demonstrated no toxicity in rats when the modified pneumococcal vaccine\u00a0was administered subcutaneously\u00a0three times\u00a0in 2-weeks at a supratherapeutic dose. [34]"}
{"id": "article-27346_57", "title": "Pneumococcal Vaccine -- Enhancing Healthcare Team Outcomes", "content": "The pneumococcal vaccine is safe and effective and can help reduce the risk of infection with certain types of pneumonia, sepsis, and meningitis. The\u00a0CDC suggests shared clinical decision-making between patients and clinicians as it has been shown to increase vaccination rates among adults. [35] All interprofessional healthcare team members, including clinicians (MDs, DOs, NPs, PAs), nursing staff, and pharmacists, should educate patients on the benefits of the pneumococcal vaccine, answer patient questions, alleviate any concerns they may have about the vaccine, and provide information for the patient in the unlikely event that they experience an adverse reaction.", "contents": "Pneumococcal Vaccine -- Enhancing Healthcare Team Outcomes. The pneumococcal vaccine is safe and effective and can help reduce the risk of infection with certain types of pneumonia, sepsis, and meningitis. The\u00a0CDC suggests shared clinical decision-making between patients and clinicians as it has been shown to increase vaccination rates among adults. [35] All interprofessional healthcare team members, including clinicians (MDs, DOs, NPs, PAs), nursing staff, and pharmacists, should educate patients on the benefits of the pneumococcal vaccine, answer patient questions, alleviate any concerns they may have about the vaccine, and provide information for the patient in the unlikely event that they experience an adverse reaction."}
{"id": "article-27346_58", "title": "Pneumococcal Vaccine -- Enhancing Healthcare Team Outcomes", "content": "Pediatricians and primary care physicians should prescribe the age-appropriate vaccine according to the latest recommendations of the CDC and ACIP. In the event of\u00a0anaphylaxis, emergency medicine physicians should rapidly stabilize the patients. All healthcare team members must also ensure the patient's medical record is updated to reflect the most recent vaccine administration, especially since clinicians, nurses, and pharmacists can all administer the vaccine in most states. This integrated teamwork and information sharing will help drive improved patient outcomes related to pneumococcal vaccination. Over the years, the vaccine has proven to be safe and effective. [36] [Level 5]", "contents": "Pneumococcal Vaccine -- Enhancing Healthcare Team Outcomes. Pediatricians and primary care physicians should prescribe the age-appropriate vaccine according to the latest recommendations of the CDC and ACIP. In the event of\u00a0anaphylaxis, emergency medicine physicians should rapidly stabilize the patients. All healthcare team members must also ensure the patient's medical record is updated to reflect the most recent vaccine administration, especially since clinicians, nurses, and pharmacists can all administer the vaccine in most states. This integrated teamwork and information sharing will help drive improved patient outcomes related to pneumococcal vaccination. Over the years, the vaccine has proven to be safe and effective. [36] [Level 5]"}
{"id": "article-27346_59", "title": "Pneumococcal Vaccine -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Pneumococcal Vaccine -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}